A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Biliary Cholangitis
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs LJN 452 (Primary)
- Indications Biliary cirrhosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis
- 01 Aug 2017 Planned End Date changed from 1 Dec 2017 to 5 May 2019.
- 10 Jun 2017 Biomarkers information updated
- 19 Oct 2015 Planned number of patients changed from 90 to 40, according to ClinicalTrials.gov record.